|
- Combining digital and automation technologies to build smart shipyards and strengthen shipbuilding capabilities
- Advancing workforce development through hands-on training and specialized engineering programs
- "Collaboration between shipbuilding and IT companies will be a catalyst for digital innovation in the U.S. shipbuilding industry"
SEOUL, South Korea, Nov. 2, 2025 /PRNewswire/ -- HD Hyundai is partnering with Germany's Siemens to accelerate the digital transformation and modernization of the U.S. shipbuilding industry.
HD Hyundai announced on Sunday, Nov. 2, that it recently signed a Memorandum of Understanding (MOU) with Siemens on the strategic collaboration for U.S. shipbuilding revitalization.
Through this partnership, the two companies aim to enhance the overall competitiveness of the U.S. shipbuilding industry by improving design quality, minimizing production risks, enhancing quality, and reducing costs.
The partnership will drive gradual technological innovation across the shipbuilding sector by advancing the digitalization of ship design, automating block assembly and installation processes, and optimizing production, quality, and process management through data-driven solutions.
In addition to technology cooperation, the two companies will jointly develop professional training programs to cultivate skilled experts in shipbuilding. HD Hyundai plans to dispatch instructors to more than thirty Siemens training facilities across the United States to deliver field-oriented, hands-on education. Building on its existing academic partnerships with leading universities such as the University of Michigan (UM) and Massachusetts Institute of Technology (MIT), HD Hyundai also plans to develop specialized curricula in engineering, digital design, and process automation. The parties also agreed to explore various opportunities for business cooperation and partnership expansion.
Since 2023, HD Hyundai has been jointly developing a manufacturing innovation platform with Siemens, a provider of industrial software, that integrates data from design to production within a single digital ecosystem. The platform enables virtual simulation of design and production processes, reducing trial and error while deriving optimized outcome.
The partnership is expected to accelerate the smart transformation of U.S. shipyards, enhancing shipbuilding competitiveness through improved quality, cost reduction, and minimized production risks.
"Maximizing production efficiency through digital and automation technologies is key to the reconstruction of the U.S. shipbuilding industry," said Moon Sangmin, Head of Global Strategy at HD Hyundai. "HD Hyundai's accumulated shipbuilding technology and Siemens' digital capabilities will contribute to creating new opportunities for the U.S. shipbuilding industry."
Meanwhile, HD Hyundai has been strengthening its cooperation network in the United States to advance the Make American Shipbuilding Great Again (MASGA) initiative — a symbol of Korea–U.S. shipbuilding collaboration. The company has established strategic partnerships with major U.S. players, including Huntington Ingalls Industries (HII) in the naval sector and Edison Chouest Offshore (ECO) in the commercial ship segment. HD Hyundai is also jointly promoting workforce development programs with leading universities such as Seoul National University, UM, and MIT.
- Combining digital and automation technologies to build smart shipyards and strengthen shipbuilding capabilities
- Advancing workforce development through hands-on training and specialized engineering programs
- "Collaboration between shipbuilding and IT companies will be a catalyst for digital innovation in the U.S. shipbuilding industry"
SEOUL, South Korea, Nov. 2, 2025 /PRNewswire/ -- HD Hyundai is partnering with Germany's Siemens to accelerate the digital transformation and modernization of the U.S. shipbuilding industry.
HD Hyundai announced on Sunday, Nov. 2, that it recently signed a Memorandum of Understanding (MOU) with Siemens on the strategic collaboration for U.S. shipbuilding revitalization.
Through this partnership, the two companies aim to enhance the overall competitiveness of the U.S. shipbuilding industry by improving design quality, minimizing production risks, enhancing quality, and reducing costs.
The partnership will drive gradual technological innovation across the shipbuilding sector by advancing the digitalization of ship design, automating block assembly and installation processes, and optimizing production, quality, and process management through data-driven solutions.
In addition to technology cooperation, the two companies will jointly develop professional training programs to cultivate skilled experts in shipbuilding. HD Hyundai plans to dispatch instructors to more than thirty Siemens training facilities across the United States to deliver field-oriented, hands-on education. Building on its existing academic partnerships with leading universities such as the University of Michigan (UM) and Massachusetts Institute of Technology (MIT), HD Hyundai also plans to develop specialized curricula in engineering, digital design, and process automation. The parties also agreed to explore various opportunities for business cooperation and partnership expansion.
Since 2023, HD Hyundai has been jointly developing a manufacturing innovation platform with Siemens, a provider of industrial software, that integrates data from design to production within a single digital ecosystem. The platform enables virtual simulation of design and production processes, reducing trial and error while deriving optimized outcome.
The partnership is expected to accelerate the smart transformation of U.S. shipyards, enhancing shipbuilding competitiveness through improved quality, cost reduction, and minimized production risks.
"Maximizing production efficiency through digital and automation technologies is key to the reconstruction of the U.S. shipbuilding industry," said Moon Sangmin, Head of Global Strategy at HD Hyundai. "HD Hyundai's accumulated shipbuilding technology and Siemens' digital capabilities will contribute to creating new opportunities for the U.S. shipbuilding industry."
Meanwhile, HD Hyundai has been strengthening its cooperation network in the United States to advance the Make American Shipbuilding Great Again (MASGA) initiative — a symbol of Korea–U.S. shipbuilding collaboration. The company has established strategic partnerships with major U.S. players, including Huntington Ingalls Industries (HII) in the naval sector and Edison Chouest Offshore (ECO) in the commercial ship segment. HD Hyundai is also jointly promoting workforce development programs with leading universities such as Seoul National University, UM, and MIT.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
HD Hyundai and Siemens Accelerate Modernization of U.S. Shipbuilding with Smart Technology
PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients. This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next‑generation antibody–drug conjugates (ADCs) and other targeted therapeutics.
Through the collaboration, NJ Bio will integrate the AJICAP™ platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP™ enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs.
AJICAP™ technology is widely recognized for its scalability, consistency, and compatibility with standard antibody production processes. By integrating this platform, NJ Bio strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end‑to‑end support, from early drug design and discovery through preclinical development.
Clients will benefit from NJ Bio's deep expertise in medicinal chemistry, bioconjugation, and biologics development, combined with the precision, reproducibility, and flexibility of the AJICAP™ platform. Based on prior technical experience working with AJICAP™ technology, NJ Bio anticipates that this collaboration will help reduce development risk, shorten timelines, and improve overall project outcomes.
"Expanding our capabilities with AJICAP™ aligns strongly with NJ Bio's mission to deliver cutting-edge, high-value solutions that accelerate our clients' discovery programs," said Julien Dugal-Tessier, the President and Chief Scientific Officer at NJ Bio. "This collaboration enables us to offer a proven, scalable site-specific conjugation platform, expand access to AJICAP™ capabilities, and support the development of novel antibody-based medicines with improved efficacy and safety profiles."
"AJICAP™ was developed to enable precise and scalable antibody conjugation, and we are excited to extend its reach through this collaboration with NJ Bio," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. "Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients."
About NJ Bio, Inc.
NJ Bio, Inc. is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania and Mumbai, India. The company provides fully integrated chemistry and biology services to biotechnology and pharmaceutical companies, supporting programs from early discovery through GMP manufacturing. With deep expertise in bioconjugation, synthetic organic chemistry, protein‑based biopharmaceuticals, and GMP manufacturing, it specializes in ADCs, targeted protein degraders (TPDs), oligo‑conjugates, and other non‑oncology conjugated therapeutics. The organization delivers customized, science‑driven solutions designed to accelerate development timelines and reduce technical risk. NJ Bio has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference. Learn more: https://njbio.com/
About Ajinomoto Bio‑Pharma Services
Ajinomoto Bio‑Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States, providing support across gene therapy, APIs, and both large‑ and small‑molecule manufacturing. The company offers a broad range of innovative platforms and capabilities—from preclinical and pilot programs through commercial supply—including high‑potency APIs (HPAPI), continuous‑flow manufacturing, oligonucleotide synthesis, biocatalysis, CORYNEX® protein expression technology, and antibody–drug conjugation (ADC) services. Learn more: https://ajibio-pharma.ajinomoto.com
For further information, please contact: HERE
Photo - https://mma.prnasia.com/media2/2947092/Bio_Aji_BioPharma_Services_Collaboration.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
